We read with interest the review article by Dr Baue1 in which he describes so clearly the problems with studies of new modulators of inflammation aimed at preventing systemic inflammatory response syndrome (SIRS) in patients in the intensive care unit, the limitations of single anti-inflammatory therapies, and the need for early identification of patients at risk.
Gosling P, Bascom JU, Zikria BA. Systemic Inflammatory Response Syndrome and Magic Bullets: Finding the Target and Improving the Aim. Arch Surg. 1998;133(3):334. doi: